Corestemchemon KRX:166480KOSDAQ
코아스템켐온 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days3
DART filings, 7 days0
Articles tracked9since Sep 11
In Q2 2026, Corestemchemon reported revenue of ₩5.4bn, down 1.7% year on year, and an operating loss of ₩4.3bn. Corestemchemon (코아스템켐온) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 4 articles. The most common catalyst was clinical & approvals (7).
Filing signals 4 quarters of losses Screener
Corestemchemon quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩5.4bn | -1.7% | −₩4.3bn margin −79.3% | −₩3.7bn |
| Q1 2026 | ₩4.3bn | -29.0% | −₩6.0bn margin −137.7% | −₩6.9bn |
| Q4 2025 derived | ₩4.9bn | +0.6% | −₩3.1bn margin −62.4% | −₩10.0bn |
| Q3 2025 | ₩3.6bn | -56.7% | −₩7.5bn margin −208.0% | −₩7.2bn |
| Q2 2025 | ₩5.5bn | -23.1% | −₩6.8bn margin −123.6% | −₩7.9bn |
| Q1 2025 | ₩6.1bn | -27.1% | −₩3.9bn margin −63.1% | −₩1.8bn |
| Q4 2024 derived | ₩4.9bn | -2.4% | −₩7.8bn margin −158.3% | ₩3.9bn |
| Q3 2024 | ₩8.3bn | +28.4% | −₩5.7bn margin −68.5% | −₩4.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Corestemchemon top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
Latest Corestemchemon news Korean headlines
-
Major코아스템켐온, 뉴로나타-알주 제조소 변경허가 신청
2 more on this story · 2 outlets
- 코아스템켐온, '뉴로나타-알주' 제조소 변경허가 신청…내년 초 공급 재개 기대메디컬투데이 · Oct 28 12:31
- 코아스템켐온, ‘뉴로나타-알주’ 제조소 변경허가 신청 완료⋯“본격적인 매출 기대”이투데이 · Oct 28 12:45
-
Major코아스템켐온 ‘뉴로나타-알’, FDA와 후속 임상 방향 구체화…3b상 추진
1 more on this story · 1 outlets
- 코아스템켐온 ‘뉴로나타-알’, FDA와 후속 임상 방향 구체화…3b상 추진이데일리 · Oct 19 16:40